Contineum Therapeutics (CTNM) Competitors $7.59 -0.31 (-3.92%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$7.90 +0.31 (+4.14%) As of 02/21/2025 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CTNM vs. CVAC, EOLS, BCYC, CDMO, ORIC, DNA, NUVB, PRTA, OPT, and CRONShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include CureVac (CVAC), Evolus (EOLS), Bicycle Therapeutics (BCYC), Avid Bioservices (CDMO), ORIC Pharmaceuticals (ORIC), Ginkgo Bioworks (DNA), Nuvation Bio (NUVB), Prothena (PRTA), Opthea (OPT), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. CureVac Evolus Bicycle Therapeutics Avid Bioservices ORIC Pharmaceuticals Ginkgo Bioworks Nuvation Bio Prothena Opthea Cronos Group Contineum Therapeutics (NASDAQ:CTNM) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability. Does the MarketBeat Community favor CTNM or CVAC? CureVac received 18 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 55.32% of users gave CureVac an outperform vote. CompanyUnderperformOutperformContineum TherapeuticsOutperform Votes8100.00% Underperform VotesNo VotesCureVacOutperform Votes2655.32% Underperform Votes2144.68% Is CTNM or CVAC more profitable? CureVac has a net margin of 20.72% compared to Contineum Therapeutics' net margin of 0.00%. CureVac's return on equity of 21.98% beat Contineum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -49.92% -20.52% CureVac 20.72%21.98%15.72% Do institutionals & insiders have more ownership in CTNM or CVAC? 17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate CTNM or CVAC? Contineum Therapeutics presently has a consensus target price of $29.25, indicating a potential upside of 285.38%. CureVac has a consensus target price of $10.00, indicating a potential upside of 203.03%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Contineum Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20CureVac 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media refer more to CTNM or CVAC? In the previous week, CureVac had 5 more articles in the media than Contineum Therapeutics. MarketBeat recorded 8 mentions for CureVac and 3 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.64 beat CureVac's score of 0.52 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, CTNM or CVAC? Contineum Therapeutics has higher earnings, but lower revenue than CureVac. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M3.91$22.72MN/AN/ACureVac$543.28M1.36-$281.58M$0.556.00 SummaryContineum Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$195.67M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E RatioN/A6.1326.4618.82Price / Sales3.91311.22453.6978.73Price / Cash5.9567.8344.0437.47Price / Book-2.046.747.634.64Net Income$22.72M$138.11M$3.18B$245.69M7 Day Performance-1.81%-2.43%-1.91%-2.66%1 Month Performance-32.29%-1.91%-0.19%-2.15%1 Year PerformanceN/A-5.03%16.70%12.90% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.9313 of 5 stars$7.59-3.9%$29.25+285.4%N/A$195.67M$50M0.0031News CoverageCVACCureVac4.0957 of 5 stars$3.71+3.6%$10.00+169.5%-3.5%$830.60M$58.18M6.751,172News CoverageEOLSEvolus3.955 of 5 stars$13.11flat$23.67+80.5%+7.0%$830.14M$248.33M-14.41170BCYCBicycle Therapeutics2.84 of 5 stars$11.84-2.8%$33.25+180.8%-49.7%$817.55M$26.98M-3.60240CDMOAvid Bioservices2.2405 of 5 stars$12.50+0.1%$12.25-2.0%+68.9%$799.18M$139.91M-5.23320High Trading VolumeORICORIC Pharmaceuticals4.5379 of 5 stars$11.23-8.3%$18.71+66.6%-25.6%$792.50MN/A-6.2480Earnings ReportAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeDNAGinkgo Bioworks0.8647 of 5 stars$13.48-5.4%$4.58-66.1%N/A$774.66M$251.46M-1.031,218Upcoming EarningsNews CoverageGap UpNUVBNuvation Bio2.0573 of 5 stars$2.29-4.0%$8.20+258.9%+23.9%$769.06MN/A-1.0560PRTAProthena2.9534 of 5 stars$14.07+0.1%$46.50+230.5%-42.5%$757.11M$91.37M-5.67130Earnings ReportAnalyst ForecastNews CoveragePositive NewsGap DownOPTOpthea2.0678 of 5 stars$5.54-3.3%$12.00+116.6%+46.8%$755.82M$120,000.000.008Upcoming EarningsCRONCronos Group1.2687 of 5 stars$1.96+1.6%$3.00+53.1%-10.0%$749.76M$87.24M-15.08450 Related Companies and Tools Related Companies CVAC Competitors EOLS Competitors BCYC Competitors CDMO Competitors ORIC Competitors DNA Competitors NUVB Competitors PRTA Competitors OPT Competitors CRON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTNM) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts